Longevity research has no shortage of compounds that extend life in a worm, fly, or mouse. The harder question is whether the effect survives when the same idea is tested in another organism.
A new cross-species screening platform makes that translation problem unusually visible. Researchers built compatible systems for testing potential lifespan-extending compounds in yeast, nematode worms, fruit flies, turquoise killifish, and mice. Across thousands of experimental conditions, they evaluated more than 400 compounds.
The result is not a list of proven anti-aging drugs. It is a demonstration of how inconsistent lifespan effects can be across species, sexes, diets, doses, and laboratory conditions.
Five models, one screening strategy
Each model answers a different kind of question.
Yeast can be screened rapidly and cheaply, but a single-celled fungus is far removed from human physiology. The nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster add whole-body tissues, behaviour, and more complex genetics while remaining suitable for large screens.
The turquoise killifish is a short-lived vertebrate. It offers a closer biological bridge to mammals while completing a lifespan experiment much faster than a mouse. Mice remain the most familiar mammalian model, but lifespan studies are expensive and can take years.
The team developed miniaturized assays for yeast, automated imaging for worms and flies, standardized drug-containing food pellets for killifish, and longitudinal monitoring for mice. Machine-learning systems helped identify survival and activity without requiring researchers to score every animal manually.
That infrastructure may be the paper’s most durable contribution. It gives researchers a way to compare results before committing to the longest and most expensive experiments.
Most effects did not travel cleanly
If a compound acts on a deeply conserved aging pathway, it might be expected to extend lifespan in several organisms. In practice, biology was less cooperative.
Some interventions produced benefits in more than one model, and the combined analysis identified compounds linked to conserved longevity pathways. But no compound was shown to extend completed lifespan significantly across all five species.
Even familiar candidates varied by context. Effects could change with sex, diet, dose, genetic background, or the way a compound was delivered. A positive result in one organism often did not predict the same result in another.
That inconsistency is not merely laboratory noise. It is information about the limits of the model.
Why lifespan studies disagree
Yeast, worms, flies, fish, and mice share many cellular systems. They regulate nutrients, repair damage, respond to stress, and recycle cellular components through pathways with ancient evolutionary roots.
Yet those pathways operate inside bodies with very different organs, immune systems, reproductive strategies, metabolic rates, and causes of death. A compound that protects a worm from one dominant source of mortality may have little effect on an older mammal facing cancer, cardiovascular disease, frailty, and infection.
Experimental design adds another layer. Food composition can alter drug effects. Male and female animals can respond differently. A dose that reaches the right tissue in a worm may be poorly absorbed or rapidly metabolized in a mammal. Starting treatment early can also produce a different result from intervening late in life.
For these reasons, the phrase “works in animals” is often too broad to be useful. The species, strain, sex, diet, dose, treatment timing, and endpoint all matter.
Evolutionary conservation is not human proof
A result that appears across distant species deserves more attention than a result confined to one model. Cross-species agreement suggests that an intervention may be acting on biology preserved through evolution.
But conserved biology is not the same as direct human applicability. Humans live for decades, take other medicines, experience varied environments, and die from a complex mixture of diseases. A compound can influence a conserved pathway while still being ineffective, unsafe, or impractical in people.
The strongest role for this platform is therefore prioritization. Compounds that perform reproducibly across several models can move higher on the list for mechanistic work, toxicology, mammalian studies, and eventually carefully designed human trials. Compounds that fail repeatedly can be deprioritized before consuming years of research.
Better screening can reduce false confidence
Longevity findings often travel from a laboratory paper to public claims far too quickly. A percentage increase in median worm lifespan can become a supplement advertisement or a headline suggesting that a human anti-aging treatment is near.
The new platform pushes in the opposite direction. It treats translation as a problem to be tested rather than assumed.
That is especially valuable because publication tends to reward positive findings. A standardized cross-species resource can make negative and context-dependent results easier to see. It can also expose cases where an apparent benefit depends on an assay artifact or one unusually favourable condition.
What the study cannot tell us
The platform does not establish that any screened compound will extend human lifespan or healthspan. It also cannot perfectly harmonize dose, exposure, metabolism, or causes of death across such different organisms.
Not every compound was tested in every species, and the mammalian arm is necessarily smaller and slower than the screens in simpler organisms. Cross-species agreement improves confidence, but it does not replace pharmacology, safety testing, or randomized human evidence.
The study’s clearest message is methodological. Aging research needs fewer leaps from a single model and more deliberate tests of whether an effect survives changing biological context.
For readers, the practical lesson is just as important. When a new compound extends lifespan in an animal, the first question should not be how soon people can take it. The first question should be whether the result can travel.
Primary study: https://doi.org/10.1016/j.celrep.2026.117897
Related reading: https://thelifespanbrief.com/2026/08/31/whatever-happened-to-senolytics/